期刊文献+

I-FABP检测在急性肠梗阻患者肠缺血坏死诊断中的价值 被引量:3

The value of I-FABP measurement in the diagnosis of intestinal ischemic in patients with acute intestinal obstruction
下载PDF
导出
摘要 目的探讨肠脂肪酸结合蛋白(I-FABP)在急性肠梗阻患者肠缺血坏死诊断中的价值。方法选取于该院治疗的128例急性肠梗阻患者(肠梗阻组),其中发生肠缺血坏死的患者53例(缺血坏死组),未发生肠缺血坏死的患者75例(非缺血坏死组),同期130例健康体检者作为对照组。对上述人群的血清I-FABP水平进行比较分析。结果肠梗阻组血清I-FABP水平和I-FABP的阳性率均高于对照组(P<0.05),缺血坏死组血清I-FABP水平和I-FABP阳性率均高于非缺血坏死组(P<0.05)。I-FABP检测用于诊断急性肠梗阻患者肠缺血坏死的ROC曲线下面积为0.805(95%CI:0.772~0.938,P<0.05)。结论 IFABP在肠梗阻患者肠缺血坏死的诊断中有较高的应用价值,值得推广。 Objective To study the value of I-FABP in discriminating intestinal ischemic in patients with acute intestinal ob- struction. Methods We compared and analyzed the level of serum 1-FABP in 128 patients with acute intestinal obstruction (ische- mic group 53 cases,non-ischemic group 75 cases) and 130 healthy people (the control group). Results The level of serum I-FABP and positive rate of I-FABP of intestinal obstruction group was statistically higher than that of the control group (P^0.05) ;level of serum I-FABP and positive rate of I-FABP of ischemic group was statistically higher than that of the non-ischemic group (P~ 0.05). ROC areas of I-FABP in discriminating intestinal ischemic in patients with acute intestinal obstruction was 0. 805 (95~CI: 0. 772--0. 938 ,P-~0.05).. Conclusion I-FABP is potentially useful for discriminating intestinal ischemic in patients with acute in- testinal obstruction.
出处 《国际检验医学杂志》 CAS 2014年第4期410-411,共2页 International Journal of Laboratory Medicine
关键词 肠脂肪酸结合蛋白 肠梗阻 肠缺血 intestinal fatty acid binding protein intestinal obstruction intestinal ischemic
  • 相关文献

参考文献9

二级参考文献62

共引文献73

同被引文献27

  • 1Teun C van den Heijkant,Bart AC Aerts,Joep A Teijink,Wim A Buurman,Misha DP Luyer.Challenges in diagnosing mesenteric ischemia[J].World Journal of Gastroenterology,2013,19(9):1338-1341. 被引量:34
  • 2曾祥泰,徐智,凌晓锋.急性缺血性肠疾病的早期诊断研究进展[J].中国现代普通外科进展,2007,10(5):438-441. 被引量:12
  • 3Griffiths B, Iain D. Sepsis, SIRS, and MODS [ J]. Surgery (Oxford), 2009, 27( 10): 446-449.
  • 4Yang Y, Yang KS, Hsann YM, et al. The effect of comorbidity and age on hospital mortality and length of stay in patients with sepsis[ J]. J Crit Care, 2010, 25 (3) :398-405.
  • 5Namas R, Zamora R, Namas R, et al. Sepsis: something old, something new, and a systems view [J]. J Crit Care, 2012,27 (3) :314. el-11.
  • 6Camilleri M, Madsen K, Spiller R, et al. Intestinal barrier function in health and gastrointestinal disease [J].Neurogastroenterol Motil, 2012,24 (6) :503-512.
  • 7Huang N, Wang F, Wang Y, et al. Ulinastatin improves survival of septic mice by suppressing inflammatory response and lymphocyte apoptosis [ J ]. J Surg Res, 2013, 182 (2) :296-302.
  • 8Costantini TW, Deree J, Loomis W, et al. Phosphodiesterase inhibition attenuates alterations to the tight junction proteins occludin and ZO-1 in immunostimulated Caco-2 intestinal monolayers [J].Life Sci,2009,84(1-2) :18-22.
  • 9Inoue K, Takano H. Urinary trypsin inhibitor as a therapeutic option for endotoxin-related inflammatory disorders [ J ]. Expert Opin Investig Drugs, 2010, 19(4) :513-520.
  • 10Cao YZ, Tu YY, Chen X, et al. Protective effect of Ulinastatin against murine models of sepsis : inhibition of TNF-a and IL-6 and augmentation of IL-10 and IL-13 [ J]. Exp Toxicol Pathol, 2012, 64(6) :543-547.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部